Drug updated on 11/16/2023
|Tablet (oral: 100 mg)
|Non-nucleoside reverse transcriptase inhibitors
|Ongoing and Completed Studies
- Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg with no prior antiretroviral treatment history, or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine.
Product Monograph / Prescribing Information
|Pifeltro (doravirine) Prescribing Information.
|Merck Sharp & Dohme LLC, Rahway, NJ
Systematic Reviews / Meta-Analyses
|Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review.
|Comparison of the Efficacy and Safety of a Doravirine-Based, Three-Drug Regimen in Treatment-Naïve HIV-1 Positive Adults: A Bayesian Network Meta-Analysis.
|Frontiers ion Pharmacology
|Efficacy and safety of doravirine in treatment-naive HIV-1-infected adults: a systematic review and meta-analysis.
|Environmental Science and Pollution Research
|Clinical review report: doravirine (Pifeltro).
Clinical Practice Guidelines
|Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States.
|Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.
|Therapeutic guidelines for antiretroviral treatment of adult HIV infection.
|British Columbia Centre for Excellence in HIV/AIDS
|2019 update of the European AIDS Clinical Society guidelines for treatment of people living with HIV version 10.0.